natgillin/translations-raw huggingface dataset:
Adverse events reported following overdose were similar in nature and distribution to those observed with therapeutic doses of Tamiflu, described in section 4.8 Undesirable effects.
Neželeni dogodki, o katerih so poročali po prevelikem odmerjanju, so bili po naravi in pogostnosti podobni tistim, ki so jih opazili pri terapevtskih odmerkih zdravila Tamiflu, opisanih v poglavju 4.8 Neželeni učinki.
Adverse events that occurred at an increased incidence of ≥5% in the supratherapeutic dose period compared with the therapeutic dose period were headache, generalised rash, and increased transaminase.
Neželeni dogodki, ki so se pojavljali z zvečano incidenco ≥5 % v obdobju po supraterapevtskem odmerku v primerjavi z obdobjem po terapevtskem odmerku, so bili glavobol, generaliziran izpuščaj in zvišane transaminaze.
Adverse events to be prioritised for reporting, i.e. fatal and life-threatening adverse reactions, unexpected severe adverse reactions, adverse events of special interest (AESI).
Neželene učinke, ki imajo pri prijavljanju prednost, tj. smrtne in življenje ogrožajoče neželene učinke, nepričakovane hude neželene učinke, neželene dogodke posebnega pomena (AESI).
Adverse events to be prioritised for reporting, i.e. fatal and life-threatening adverse reactions, unexpected severe adverse reactions, adverse events of special interest (AESI).
Neželene učinke, ki imajo pri prijavljanju prednost, tj. smrtne in življenje ogrožajoče neželene učinke, nepričakovane hude neželene učinke, neželene učinke posebnega pomena (AESI).
Adverse events(s)
Neželeni učinek (učinki)
adverse events, the combination of
Med sočasno uporabo kombinacije
Adverse re action
Neželeni učinek
Adverse reaction
disurija
Adverse Reaction
maligni melanom
ADVERSE REACTION
NEŽELENI UČINEK
Adverse reaction
Nežele ni učinek
Adverse reaction
neželen učinek
Adverse reaction
Neželeni učinek zdravila
Adverse reaction
Neželeni učinki
Adverse reaction
Neželni učinek
Adverse Reaction
odpoved jeter1)
Adverse reaction
Preiskave
Adverse reaction
reakcija, povezana z infundiranjem
Adverse reaction
renalna hipoplazija
Adverse reaction
Učinek na koncentracijo
Adverse Reaction
V preglednici predstavljeni neželeni učinki
Adverse reaction
vrtoglavica
Adverse reaction (fenofibrate)
Neželeni učinek (fenofibrat)
Adverse reaction (MedDRA Preferred Term)
Neželeni učinek (navedba po MedDRA)
Adverse Reaction (Medicinal Product*)
Neželeni učinki (zdravilo*)
Adverse reaction (Pravastatin)
Neželeni učinek (pravastatin)
Adverse Reaction (Preferred Term)
Neželeni učinek
Adverse reaction after previous HALAVEN administration
Neželeni učinki po predhodnem dajanju zdravila HALAVEN
Adverse reaction and severity
Neželeni učinki in resnost
Adverse Reaction Frequency of adverse reactions1 Gastrointestinal disorders
Neželeni učinek Pogostnost neželenega učinka1 Bolezni prebavil
Adverse reaction frequency was estimated primarily based on summation of unique Cinryze-related adverse events reported across 8 completed clinical studies in HAE subjects.
Pogostnost neželenih učinkov so ocenili predvsem na podlagi povzetka različnih neželenih učinkov, povezanih z zdravilom Cinryze, o katerih so poročali v 8 dokončanih kliničnih študijah pri osebah s HAE.
Adverse reaction frequency**
Pogostnost neželenih učinkov
Adverse Reaction Management Guide
Priročnik za ukrepanje v primeru pojava neželenih učinkov
Adverse Reaction Rates in Retroperitoneal or Intra-Abdominal Surgery Study
Stopnje neželenih učinkov v študiji uporabe pri retroperitonealnih ali intraabdominalnih kirurških posegih
Adverse reaction rates reported after either vaccination dose (1st, 2nd or booster) were similar.
Stopnje neželenih učinkov, o katerih so poročali po vseh odmerkih cepljenja (1., 2. ali poživitvenem), so bile podobne.
Adverse reaction terminology is based upon the Medical Dictionary for Regulatory Activities (MedDRA)
Terminologija neželenih učinkov temelji na medicinskem slovarju za regulatorne aktivnosti (MedDRA - Medical Dictionary for Regulatory Activities)
Adverse reaction terms
Neželeni učinki
Adverse reaction(s)
Neželeni učinek/učinki
Adverse Reaction(s)
Neželeni učinki
adverse reaction)
difosfonate značilen neželeni učinek)
ADVERSE REACTION*
NEŽELENI UČINKI
Adverse reaction/event
Neželeni učinki
Adverse reactiona
Neželeni učineka
Adverse reactions
Aukaverkun
ADVERSE REACTIONS
NEZAŽELENI UČINKI
ADVERSE REACTIONS
NEŽELENI U ČINKI
Adverse reactions
Neželene reakcije
Adverse reactions
Neželeni učinek
Adverse reactions
odpoved dihanja
adverse reactions
Pogosti neželeni učinki
Adverse Reactions (ARs) have been collected from one phase I study with healthy subjects (n = 28) and two phase III studies in patients with primary immunodeficiency (n = 100) with Hizentra.
Neželeni učinki so bili zbrani v študiji 1. faze z zdravimi preiskovanci (n = 28) in dveh študijah 3. faze z bolniki s primarno imunsko pomanjkljivostjo (n = 100) z zdravilom Hizentra.
Adverse reactions (fenofibrate)
Neželeni učinki (fenofibrat)
Adverse reactions (fenofibrate)
zvišana raven
Adverse reactions (for all age groups) considered as being at least possibly related to vaccination have been categorised by frequency.
Neželene učinke (za vse starostne skupine), ocenjene kot vsaj morda povezane s cepljenjem, so razvrstili po pogostnosti.
Adverse reactions (frequency and seriousness)
4.6. Neželeni učinki (pogostost in resnost)
Adverse reactions (frequency and seriousness)
4.6. Stranski učinki (pogostost in resnost)
Adverse reactions (frequency and seriousness)
Stranski učinki (pogostnost in resnost)
Adverse reactions (frequency and seriousness)
Stranski učinki (pogostost in resnost)
Adverse reactions (frequency and seriousness) For dogs and cats:
Neželeni učinki (pogostost in resnost) Za pse in mačke:
Adverse reactions (frequency and seriousness) Rabbits:
Neželeni učinki (pogostost in resnost) Kunci:
Adverse reactions (frequency and seriousness)*
Neželeni učinki (pogostost in resnost)
Adverse reactions (frequency)
Neželeni učinki (pogostnost)
Adverse reactions (frequency* and seriousness)
Neželeni učinki (pogostost in resnost)
Adverse reactions (frequency* and seriousness)
Neželeni učinki (pogostost* in resnost)
Adverse Reactions (Infants, Children and Adolescents)
Neželeni učinki (dojenčki, otroci in mladostniki)
Adverse reactions additionally reported after booster vaccination of primary series and/or catch-up vaccination:
Neželeni učinki, ki so bili dodatno poročani po obnovitvenem cepljenju po primarnem zaporedju cepljenja in/ali cepljenju določene starostne skupine, ki ni zajeta v program cepljenja:
Adverse reactions additionally reported from post–marketing experience are also listed.
Prav tako so navedeni dodatni neželeni učinki, o katerih so poročali po pridobitvi dovoljenja za promet.
Adverse reactions affecting the MedDRA system organ class ‘Blood and lymphatic system disorders’ subsided during continued nitisinone treatment.
Neželeni učinki, ki vplivajo na organske sisteme v skupini bolezni krvi in limfatičnega sistema, so pri nadaljnjem zdravljenju z nitizinonom izzveneli.
Adverse reactions and their frequencies are reported in table 1.
Neželeni učinki in njihove pogostnosti so navedeni v preglednici 1.
Adverse reactions are classified according to frequency and System Organ Class.
Neželeni učinki so opredeljeni po pogostnosti in glede na organske sisteme.
Adverse reactions are classified according to MedDRA System Organ Class and frequency.
Neželeni učinki so razvrščeni po organskih sistemih MedDRA in pogostnosti.
Adverse reactions are defined as those adverse events that occurred at a higher frequency in the dinutuximab, GM- CSF, IL-2 and isotretinoin-treated group compared with the isotretinoin-treated control group during the ANBL0032 randomised, controlled, pivotal study, and that have a plausible mechanistic relationship to treatment with dinutuximab.
Neželeni učinki so tiste neželene reakcije, ki so se pojavile bolj pogosto v skupini bolnikov, zdravljenih z dinutuksimabom, GM-CSF, IL-2 in izotretinoin, v primerjavi s kontrolno skupino, ki je bila zdravljena z izotretinoinom med randomizirano, kontrolirano osrednjo študijo ANBL0032, in ki so vzročno povezani z zdravljenjem z dinutuksimabom.
Adverse reactions are listed according to MedDRA system organ class and frequency category.
Neželeni učinki so navedeni po organskih sistemih in pogostnosti po MedDRA.
Adverse reactions are listed according to the following frequencies: Very common: ≥ 1/10
Neželeni učinki so navedeni skladno z naslednjimi pogostnostmi: Zelo pogosti: ≥ 1/10
Adverse reactions are listed according to the following frequency: Very Common (≥1/10)
Neželeni učinki so razvrščeni glede na naslednje opredelitve pogostnosti: Zelo pogosti (≥1/10)
Adverse reactions are listed according to the following frequency: Very Common (≥1/10)
Neželni učinki so navedeni po naslednji pogostnosti: zelo pogosti (≥1/10)
Adverse reactions are listed according to the MedDRA frequency convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (1/1,000 to <1/100), rare (1/10,000 to <1/1,000) and not known (can not be estimated from available data).
Neželeni učinki so razvrščeni po pogostnosti glede na klasifikacijo MedDRA: zelo pogosti (> 1/10), pogosti (> 1/100 do < 1/10), občasni (> 1/1.000 do < 1/100), redki (> 1/10.000 do < 1/1.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are listed according to the MedDRA frequency convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (1/1,000 to <1/100), rare (1/10,000 to <1/1,000) and not known (can not be estimated from available data).
Neželeni učinki so razvrščeni po pogostnosti glede na klasifikacijo MedDRA: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are listed below by MedDRA body system organ class and by frequency.
Neželeni učinki so navedeni spodaj po organskih sistemih MedDRA in pogostnosti.
Adverse reactions are listed below by MedDRA body system organ class.
Neželeni učinki so navedeni spodaj po organskih sistemih MedDRA.
Adverse reactions are listed below by MedDRA system organ class and by frequency.
Neželeni učinki so navedeni spodaj po organskih sistemih MedDRA in pogostnosti.
Adverse reactions are listed below by system organ class and frequency.
Neželeni učinki so našteti spodaj glede na organski sistem in pogostost.
Adverse reactions are listed below in Table 1 by system organ class and frequency (frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so našteti spodaj v preglednici 1 po organskih sistemih in pogostnosti (pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov)).
Adverse reactions are listed below using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so našteti po naslednji razvrstitvi: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznano (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are listed below using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so našteti po naslednji razvrstitvi: zelo pogosti (≥ 1/10), pogosti (≥ 1/100, < 1/10), občasni (≥ 1/1.000, < 1/100), redki (≥ 1/10.000, < 1/1.000), zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are listed below, by system organ class and absolute frequency (all reported events).
Spodaj so naveden neželeni učinki, razvrščeni po organskih sistemih in absolutni pogostnosti (vsi dogodki, o katerih so poročali).
Adverse reactions are listed below, by system organ class and absolute frequency (all reported events).
V nadaljevanju navajamo neželene učinke, razvrščene v razrede po organskih sistemih in po absolutni pogostnosti (vsi neželeni učinki, o katerih so poročali).
Adverse reactions are listed by MedDRA body system organ class and by frequency: Very common (_≥1/10); Common (≥1/100 to < 1/10); and Uncommon (≥ 1/1,000 to < 1/100).
Neželeni učinki so navedeni po MedDRA klacifikaciji glede na organski sistem in pogostnost: zelo pogosti (≥1/10); pogosti (≥1/100 do < 1/10), ter občasni (≥1/1,000 do <1/100).
Adverse reactions are listed by system organ class and frequency (common (1/100 to <1/10), uncommon (1/1,000 to <1/100) and rare (1/10,000 to <1/1,000)) in the table below.
V spodnji preglednici so neželeni učinki navedeni po organskih sistemih in pogostosti (pogosti (1/100 do <1/10), občasni (1/1.000 do <1/100) in redki (1/10.000 to <1/1.000)).
Adverse reactions are listed in Table 1 below
Neželeni učinki so navedeni v spodnji preglednici 1.
Adverse reactions are listed in Table 1below.
Neželeni učinki so navedeni v spodnji preglednici 1.
Adverse reactions are listed in table 2 according to MedDRA system organ class and frequency categories.
Neželeni učinki so navedeni v preglednici 2 po organskih sistemih in kategorijah pogostnosti MedDRA.
Adverse reactions are listed in Table 2 according to MedDRA system organ class and frequency categories.
Neželeni učinki v preglednici 2 so razvrščeni po dogovoru MedDRA po organskih sistemih in pogostnosti.
Adverse reactions are listed in Table 3 below.
Neželeni učinki so navedeni v spodnji preglednici 2.
Adverse reactions are listed inTable 1 below.
Neželeni učinki so navedeni v spodnji preglednici 1.
Adverse reactions are presented according to the MedDRA System Organ Classification and frequency convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to
Neželeni učinki so skladno s terminologijo MedDRA razvrščeni po organskih sistemih in pogostnosti: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do
Adverse reactions are presented according to the MedDRA system organ classification.
Neželeni učinki so razvrščeni po organskih sistemih v skladu s klasifikacijo MedDRA.
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000).
Neželeni učinki so navedeni po padajoči resnosti in njihova pogostnost je opredeljena takole: zelo pogosti: (≥1/10); pogosti: (≥1/100 do <1/10); občasni: (≥1/1.000 do <1/100); redki: (≥1/10.000 do <1/1.000) in zelo redki: (<1/10.000).
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to<1/100); rare (≥1/10,000 to<1/1,000) and very rare (<1/10,000)
Neželeni učinki so razporejeni po padajoči resnosti ter sledeči pogostnosti: zelo pogosti: (≥1/10); pogosti: (≥1/100 do <1/10); občasni: (≥1/1.000 do <1/100); redki: (≥1/10.000 do <1/1.000) in zelo redki: (<1/10.000).
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥ 1/10), common (≥1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥1/10,000 to
Neželeni učinki so razporejeni glede na organske sisteme ob uporabi naslednjih navedb: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so razporejeni glede na organske sisteme ob uporabi naslednjih navedb: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥1/10,000 to <1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so razporejeni glede na organske sisteme ob uporabi naslednjih navedb: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to
Neželeni učinki so razporejeni glede na organske sisteme ob uporabi naslednjega dogovora: zelo pogosti (≥1/10); pogosti (≥1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do
Adverse reactions are ranked according to system organ class, using the following convention:very common ( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1,000 to < 1/100), rare ( 1/10,000 to
Neželeni učinki so razporejeni glede na organske sisteme ob uporabi naslednjega dogovora: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do
Adverse reactions are ranked below using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Neželeni učinki so spodaj razvrščeni po naslednjem dogovoru: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are ranked by system organ class and frequency ([very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000)]).
Neželeni učinki so razvrščeni po organskem sistemu in pogostnosti ([zelo pogosti (≥1/10); pogosti (≥1/100 do 1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000)]).
Adverse reactions are ranked under headings of frequency using the following convention:
Neželeni učinki so razvrščeni po pogostnosti v skladu z naslednjim dogovorom:
Adverse reactions are ranked under headings of frequency using the following conventions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10000 to <1/1000), very rare (<1/10000).
Neželeni učinki so navedeni glede na pogostnost ob upoštevanju sledečih dogovorov: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000).
Adverse reactions are ranked under headings of frequency using the following conventions: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1000, <1/100), rare (≥1/10000, <1/1000), very rare (<1/10000).
Neželeni učinki so navedeni glede na pogostnost ob upoštevanju sledečih dogovorov: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention:
Neželeni učinki so razvrščeni glede na padajočo pogostnost, najprej najpogostejši, skladno z naslednjim dogovorom:
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so razvrščeni glede na pogostnost, najprej najpogostejši, in to po naslednjem dogovoru: zelo pogosti (1/10), pogosti (1/100 do <1/10), občasni (1/1.000 do <1/100), redki (1/10.000 do <1/1.000), zelo redki (<1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so razvrščeni glede na pogostnost, najprej najpogostejši, in to po naslednjem dogovoru: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so razvrščeni glede na pogostnost, najprej najpogostejši, in to po naslednjem dogovoru: zelo pogosti ( 1/10), pogosti ( 1/100 do < 1/10), občasni ( 1/1.000 do < 1/100), redki ( 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so razvrščeni po oznakah pogostnosti, najpogostejši najprej, upoštevaje naslednji dogovor: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), ni znano (ni mogoče oceniti na podlagi podatkov, ki so na voljo).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common 1/10), common 1/100 to <1/10), uncommon 1/1,000 to <1/100), rare 1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
V razvrstitvah pogostnosti so neželeni učinki navedeni po padajoči resnosti po naslednjem dogovoru: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Adverse reactions associated with macitentan obtained from this clinical study are tabulated below.
Neželeni učinki, povezani z macitentanom, ki so jih pridobili v tej klinični študiji, so predstavljeni v spodnji preglednici.
Adverse reactions associated with MEPACT in ≥ 1/100 patients
Neželeni učinki, povezani z zdravilom MEPACT pri ≥ 1/100 bolnikih
Adverse reactions associated with PR interval prolongation (e.g.
Lahko se pojavijo neželeni učinki, povezani s podaljšanjem intervala PR (npr.
Adverse reactions associated with the mode of action of selexipag have been observed frequently, in particular during the phase of individualised dose titration, and are tabulated below:
Neželene učinke, povezane z načinom delovanja seleksipaga, so opazili pogosto, zlasti med fazo individualiziranega titriranja odmerka, in so povzeti spodaj:
Adverse reactions associated with the use of ritonavir as a pharmacokinetic enhancer are dependent on the specific co-administered PI.
Neželeni učinki, povezani z uporabo ritonavirja kot farmakokinetičnega stopnjevalca, so odvisni od specifičnega sočasno uporabljanega zaviralca proteaz.